A Case Report of Iloperidone-induced Sleep-related Eating Disorder
Hani Raoul Khouzam*
Department of Psychiatry, Sacramento VA Medical Center and UC Davis Health, Sacramento, California, USA
*Corresponding Author: Hani Raoul Khouzam, MD;MPH. Staff Psychiatrist Department of Psychiatry, Sacramento VA Medical Center Clinical professor of Psychiatry and Medicine, UC Davis Health, Sacramento, California USA.
August 21, 2021; Published: August 30, 2021
Sleep-related eating disorder is a Non-Rapid Eye Movement Sleep Arousal Disorders characterized by recurrent episodes of nocturnal eating or drinking after an arousal from the Non-Rapid Eye Movement (NREM) sleep stage. Several medications, including atypical antipsychotics, have been reported to induce sleep-related eating disorder. This case report illustrates the development of sleep -related eating disorder during treatment with the atypical antipsychotic Iloperidone. It also reviews Iloperidone core mechanisms of action of and propose a possible link between its effects on 5-hydroxytryptamine-2A and 2C (5-HT2A) and (5-HT2C) neuroreceptors and the development of Sleep-related eating disorder.
Keywords: Schizophrenia; Sleep-related Eating Disorder; Atypical Antipsychotics; Iloperidone; Treatment
- American Psychiatric Association. The Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Washington, DC: American Psychiatric Association (2013).
- Chiaro G., et al. “Treatment of sleep-related eating disorder”. Current Treatment Options in Neurology 8 (2015): 361.
- Inoue Y. “Sleep-related eating disorder and its associated conditions”. Psychiatry Clinical Neuroscience6 (2015): 309-320.
- American Academy of Sleep Medicine. The International Classification of Sleep Disorders: diagnostic and coding manual. 2nd ed. Westchester, IL: American Academy of Sleep Medicine (2005).
- Schenck CH., et al. “Sleep-related eating disorders: polysomnographic correlates of a heterogeneous syndrome distinct from daytime eating disorders”. Sleep 14 (1991): 419-431.
- Schenck C., et al. “Additional categories of sleep-related eating disorders and the status of treatment”. Sleep 16 (1993): 457-466.
- Morgenthaler TI and Silber MH. “Amnestic sleep-related eating disorder associated with zolpidem”. Sleep Medicine 3 (2002): 323-327.
- Yun CH and Ji KH. “Zolpidem-induced sleep-related eating disorder”. Journal of Neurological Science 288 (2010): 200-201.
- Paquet V., et al. “Sleep-related eating disorder induced by olanzapine”. The Journal of Clinical Psychiatry 63 (2002): 597.
- Lu M and Shen W. “Sleep-related eating disorder induced by risperidone”. The Journal of Clinical Psychiatry 65 (2004): 273-274.
- Heathman JC and Neal DW. “Sleep related eating disorder associated with quetiapine”. The Journal of Clinical Psychopharmacology 34 (2014): 658-660.
- Kobayashi N and Takano M. “Aripiprazole-induced sleep-related eating disorder: a case report”. Journal of Medical Case Reports 1 (2018): 91.
- McGrath J., et al. “Schizophrenia: a concise overview of incidence, prevalence, and mortality”. Epidemiology Review 30 (2008): 67-76.
- Potkin SG., et al. “The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research”. NPJ Schizophrenia1 (2020): 1.
- Weiden PJ. Iloperidone for the treatment of schizophrenia: an updated clinical review”. Clinical Schizophrenia and Related Psychoses 1 (2012): 34-44.
- Howes O D., et al. “Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology”. American Journal of Psychiatry3 (2017): 216-229.
- Bishop JR and Bishop DL. “Iloperidone for the treatment of schizophrenia”. Drugs Today (Barc)8 (2010): 567-579.
- Crabtree BL and Montgomery J. “Iloperidone for the management of adults with schizophrenia”. Clinical Therapy3 (2011): 330-345.
- Musil R., et al. “Weight gain and antipsychotics: a drug safety review”. Expert Opinion on Drug Safety 1 (2015): 73-96.
- Seeman M. “Sleepwalking, a possible side effect of antipsychotic medication”. Psychiatric Quality 82 (2011): 59-67.
- Ichikawa J., et al. “Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism”. Brain Research 956 (2002): 349-357.
- Puig MV., et al. “Serotonin modulates fast-spiking interneuron and synchronous activity in the rat prefrontal cortex through 5-HT1A and 5-HT2A receptors”. Journal of Neuroscience 30 (2010): 2211-2222.
- Heisler LK., et al. “Serotonin 5-HT (2C) receptors regulate anxiety-like behavior”. Genes, Brain and Behavior 6 (2007): 491-496.
- Nonogaki K., et al. “Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene”. Nature Medicine 4 (1998): 1152-1156.
- Uwaifo GI. “Obesity-associated hypertension. Contemporary Endocrinology Endocrine Hypertension”. Edited by: Koch CA, Chrousos GP. New York: Springer (2013): 251-288.